GH002

About GH Research

GH Research is an Irish biotech company founded in 2018 with a mission to revolutionize the treatment of severe psychiatric disorders through its innovative mebufotenin-based platform. Its core achievement is the development of the Individualized Dosing Regimen (IDR), which has demonstrated high remission rates in early trials for treatment-resistant depression. The company's strategy is to advance its lead inhaled formulation, GH001, through late-stage clinical development for multiple indications, leveraging its strong intellectual property portfolio and aiming to address a massive unmet need with a potentially paradigm-shifting therapy.

Therapeutic Areas

Other Not Specified Drugs